{"success":true,"data":{"pressRelease":{"id":"3940","rtpr_id":"nGNX3JldYW","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","author":"Globe Newswire","published_at":"2026-04-22T03:06:31.094Z","article_body":"* Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased\nbetween January 19, 2026 and March 24, 2025\n* When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026\n* Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy\nclaims in advertisement\nNEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti\n(https://ksfcounsel.com/), LLC (“KSF”) and KSF partner, former Attorney\nGeneral of Louisiana, Charles C. Foti, Jr., remind investors with substantial\nlosses that they have until May 26, 2026 to file lead plaintiff applications\nin a securities class action lawsuit against ImmunityBio\n(https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/), Inc. (NasdaqGS: IBRX)\n(“ImmunityBio” or the “Company”), if they purchased or otherwise\nacquired the Company’s securities between January 19, 2026 and March 24,\n2026, inclusive (the “Class Period”). This action is pending in the United\nStates District Court for the Central District of California.\n\nWhat You May Do\n\nIf you purchased securities of ImmunityBio and would like to discuss your\nlegal rights and how this case might affect you and your right to recover for\nyour economic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. If you wish to\nserve as a lead plaintiff in this class action, you must petition the Court by\nMay 26, 2026.\n\nAbout the Lawsuit\n\nImmunityBio and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.  \n\nOn March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food\nand Drug Administration to CEO Richard Adcock was made public, stating that a\ntelevision advertisement and podcast misrepresented Anktiva and resulted in\nits distribution violating the Federal Food, Drug, and Cosmetic Act. The\nletter also reportedly noted that the violations “are concerning from a\npublic health perspective because the promotional communications create a\nmisleading impression that Anktiva, a treatment for a certain type of bladder\ncancer, can cure and even prevent all cancer.”\n\nOn this news, the price of ImmunityBio’s shares fell $1.98 per share, or\n21%, to close at $7.42 per share on March 24, 2026.\n\nThe case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.\n\nAbout Kahn Swick & Foti (https://www.youtube.com/watch?v=ERl52xsyj0s), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook\n(https://www.facebook.com/profile.php?id=61575733915628) || Instagram\n(https://www.instagram.com/kahn_swick_and_foti/) || YouTube\n(https://www.youtube.com/@kahnswickandfoti) || TikTok\n(https://www.tiktok.com/@kahn.swick.foti) || LinkedIn\n(https://www.linkedin.com/company/ksfcounsel)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b66e75b8-42a3-4666-b8fa-64a468417619)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3JldYW","title":"ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC","author":"Globe Newswire","ticker":"IBRX","created":"2026-04-22T03:06:31.094Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"* Who is Involved: ImmunityBio, Inc. (NasdaqGS: IBRX) investors that purchased\nbetween January 19, 2026 and March 24, 2025\n* When to Act: Deadline to file Lead Plaintiff applications is May 26, 2026\n* Basis: ImmunityBio shares fell on FDA warning letter over cancer therapy\nclaims in advertisement\nNEW YORK and NEW ORLEANS, April 21, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti\n(https://ksfcounsel.com/), LLC (“KSF”) and KSF partner, former Attorney\nGeneral of Louisiana, Charles C. Foti, Jr., remind investors with substantial\nlosses that they have until May 26, 2026 to file lead plaintiff applications\nin a securities class action lawsuit against ImmunityBio\n(https://ksfcounsel.com/cases/nasdaqgs-ibrx-2/), Inc. (NasdaqGS: IBRX)\n(“ImmunityBio” or the “Company”), if they purchased or otherwise\nacquired the Company’s securities between January 19, 2026 and March 24,\n2026, inclusive (the “Class Period”). This action is pending in the United\nStates District Court for the Central District of California.\n\nWhat You May Do\n\nIf you purchased securities of ImmunityBio and would like to discuss your\nlegal rights and how this case might affect you and your right to recover for\nyour economic loss, you may, without obligation or cost to you, contact KSF\nManaging Partner Lewis Kahn toll-free at 1-877-515-1850 or via email\n(lewis.kahn@ksfcounsel.com), or visit\nhttps://ksfcounsel.com/cases/nasdaqgs-ibrx-2/ to learn more. If you wish to\nserve as a lead plaintiff in this class action, you must petition the Court by\nMay 26, 2026.\n\nAbout the Lawsuit\n\nImmunityBio and certain of its executives are charged with failing to disclose\nmaterial information during the Class Period, violating federal securities\nlaws.  \n\nOn March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food\nand Drug Administration to CEO Richard Adcock was made public, stating that a\ntelevision advertisement and podcast misrepresented Anktiva and resulted in\nits distribution violating the Federal Food, Drug, and Cosmetic Act. The\nletter also reportedly noted that the violations “are concerning from a\npublic health perspective because the promotional communications create a\nmisleading impression that Anktiva, a treatment for a certain type of bladder\ncancer, can cure and even prevent all cancer.”\n\nOn this news, the price of ImmunityBio’s shares fell $1.98 per share, or\n21%, to close at $7.42 per share on March 24, 2026.\n\nThe case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.\n\nAbout Kahn Swick & Foti (https://www.youtube.com/watch?v=ERl52xsyj0s), LLC\n\nKSF, whose partners include former Louisiana Attorney General Charles C. Foti,\nJr., is one of the nation's premier boutique securities litigation law firms.\nThis past year, KSF was ranked by SCAS among the top 10 firms nationally based\nupon total settlement value. KSF serves a variety of clients, including public\nand private institutional investors, and retail investors - in seeking\nrecoveries for investment losses emanating from corporate fraud or malfeasance\nby publicly traded companies. KSF has offices in New York, Delaware,\nCalifornia, Louisiana, Chicago, and a representative office in Luxembourg.\n\nTOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services\n\nTo learn more about KSF, you may visit www.ksfcounsel.com.\n\nContact:\n\nKahn Swick & Foti, LLC\nLewis Kahn, Managing Partner\nlewis.kahn@ksfcounsel.com\n1-877-515-1850\n1100 Poydras St., Suite 960\nNew Orleans, LA 70163\n\nCONNECT WITH US: Facebook\n(https://www.facebook.com/profile.php?id=61575733915628) || Instagram\n(https://www.instagram.com/kahn_swick_and_foti/) || YouTube\n(https://www.youtube.com/@kahnswickandfoti) || TikTok\n(https://www.tiktok.com/@kahn.swick.foti) || LinkedIn\n(https://www.linkedin.com/company/ksfcounsel)\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b66e75b8-42a3-4666-b8fa-64a468417619)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T03:06:31.146101032Z","server_sent_at_ms":1776827191146},"received_at":"2026-04-22T03:06:31.198Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}